Combination of Icaritin and TACE Enhances Survival in Advanced HCC
Overview
This study demonstrates that the combination of Icaritin and transarterial chemoembolization (TACE) significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) compared to TACE alone. The findings suggest that Icaritin may enhance the therapeutic efficacy of TACE in this high-risk patient population.
Background
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, particularly in patients with macrovascular invasion (MVI), which is associated with poor prognosis. Transarterial chemoembolization (TACE) is a common treatment for HCC, but its effectiveness can be limited in advanced stages. The integration of novel agents like Icaritin may provide additional survival benefits, warranting investigation into combination therapies.
Data Highlights
Outcome
TACE + Icaritin
TACE Alone
P-value
Median OS (months)
16.3
13.3
0.020
Median PFS (months)
8.5
7.6
0.006
Disease Control Rate (DCR)
84.0%
72.2%
0.015
Key Findings
The Icaritin–TACE group had a median OS of 16.3 months compared to 13.3 months for TACE alone (P = 0.020).
Median PFS was 8.5 months for the Icaritin–TACE group versus 7.6 months for TACE alone (P = 0.006).
The disease control rate was significantly higher in the Icaritin–TACE group at 84.0% compared to 72.2% in the TACE group (P = 0.015).
Independent predictors of OS included ECOG performance status, alpha-fetoprotein levels, number of lesions, and maximum lesion diameter.
Lesion count was independently associated with PFS.
The overall incidence of adverse events was similar between both treatment groups.
Clinical Implications
The findings support the use of Icaritin in combination with TACE for patients with advanced HCC and MVI, potentially leading to improved survival outcomes. Clinicians should consider this combination therapy as part of a multidisciplinary approach to managing high-risk HCC patients.
Conclusion
The combination of Icaritin and TACE offers a promising strategy to enhance survival in patients with advanced HCC with macrovascular invasion. Further studies are warranted to confirm these findings and optimize treatment protocols.
